摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-[2-[1-(4-chlorophenyl)triazol-4-yl]ethyl]-3,5-bis(trifluoromethyl)benzamide | 1207114-04-2

中文名称
——
中文别名
——
英文名称
N-[2-[1-(4-chlorophenyl)triazol-4-yl]ethyl]-3,5-bis(trifluoromethyl)benzamide
英文别名
——
N-[2-[1-(4-chlorophenyl)triazol-4-yl]ethyl]-3,5-bis(trifluoromethyl)benzamide化学式
CAS
1207114-04-2
化学式
C19H13ClF6N4O
mdl
——
分子量
462.782
InChiKey
TZEGHRGTHUXCBP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5
  • 重原子数:
    31
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.21
  • 拓扑面积:
    59.8
  • 氢给体数:
    1
  • 氢受体数:
    9

反应信息

  • 作为产物:
    描述:
    1-叠氮-4-氯苯N-(but-3-yn-1-yl)-3,5-bis(trifluoromethyl)benzamidecopper(II) sulfate维生素 C 作用下, 以 叔丁醇 为溶剂, 反应 48.0h, 以10%的产率得到N-[2-[1-(4-chlorophenyl)triazol-4-yl]ethyl]-3,5-bis(trifluoromethyl)benzamide
    参考文献:
    名称:
    Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423
    摘要:
    We recently identified bis(amide) CCG-1423 (1) as a novel inhibitor of RhoA/C-mediated gene transcription that is capable of inhibiting invasion of PC-3 prostate cancer cells in a Matrigel model of metastasis. An initial structure-activity relationship study focusing on bioisosteric replacement of the amides and conformational restriction identified two compounds, 4g and 8, with improved selectivity for inhibition of RhoA/C-mediated gene transcription and attenuated cytotoxicity relative to 1. Both compounds were also capable of inhibiting cell invasion with equal efficacy to 1 but with less attendant cytotoxicity. (C) 2009 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2009.11.056
点击查看最新优质反应信息

文献信息

  • METHODS AND COMPOSITIONS FOR MODULATING RHO-MEDIATED GENE TRANSCRIPTION
    申请人:Neubig Richard
    公开号:US20120252792A1
    公开(公告)日:2012-10-04
    The invention provides methods, compositions, and kits for the inhibition of members of the Rho GTPase family. Specifically, the invention provides methods, compositions and kits for the inhibition of RhoA and/or RhoC transcriptional signalling. The invention finds use in treatment of Rho-mediated disease states (e.g., tumor metastasis, inflammation, inflammatory disease), Rho-mediated biological conditions, and in cell signaling research.
    本发明提供了抑制Rho GTPase家族成员的方法、组合物和试剂盒。具体来说,本发明提供了抑制RhoA和/或RhoC转录信号的方法、组合物和试剂盒。本发明可用于治疗Rho介导的疾病状态(例如肿瘤转移、炎症、炎症性疾病)、Rho介导的生物条件以及细胞信号研究。
  • [EN] METHODS AND COMPOSITIONS FOR INHIBITING RHO-MEDIATED DISEASES AND CONDITIONS<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR INHIBER DES MALADIES ET DES ÉTATS À MÉDIATION PAR RHO
    申请人:UNIV MICHIGAN
    公开号:WO2011035143A2
    公开(公告)日:2011-03-24
    The invention provides methods, compositions, and kits for the inhibition of members of the Rho GTPase family. Specifically, the invention provides methods, compositions and kits for the inhibition of RhoA and/or RhoC transcriptional signalling. The invention finds use in treatment of Rho-mediated disease states (e.g., tumor metastasis, inflammation, inflammatory disease), Rho-mediated biological conditions, and in cell signaling research.
查看更多